Daniel Gesua Sive Salvadori - 23 Dec 2021 Form 4 Insider Report for ABBOTT LABORATORIES (ABT)

Role
EXECUTIVE VICE PRESIDENT
Signature
/s/ Daniel Gesua Sive Salvadori by Jessica H. Paik, Attorney-in-Fact
Issuer symbol
ABT
Transactions as of
23 Dec 2021
Net transactions value
-$5,890,766
Form type
4
Filing time
28 Dec 2021, 16:20:56 UTC
Previous filing
15 Dec 2021
Next filing
23 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABT Common shares without par value Options Exercise $912,806 +23,771 +23% $38.40 127,702 23 Dec 2021 Direct
transaction ABT Common shares without par value Options Exercise $1,386,568 +31,229 +24% $44.40 158,931 23 Dec 2021 Direct
transaction ABT Common shares without par value Sale $8,190,140 -58,501 -37% $140.00 100,430 23 Dec 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABT Option (right to buy) Options Exercise $0 -23,771 -50% $0.000000 23,771 23 Dec 2021 Common Shares 23,771 $38.40 Direct F1
transaction ABT Option (right to buy) Options Exercise $0 -31,229 -29% $0.000000 75,591 23 Dec 2021 Common Shares 31,229 $44.40 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.

Remarks:

These transactions were made pursuant to a previously adopted plan complying with Rule 10b5-1(c).